Alpha Cognition (OTC:ACOGF – Get Free Report) announced its quarterly earnings data on Monday. The company reported C($0.01) EPS for the quarter, beating the consensus estimate of C($0.04) by C$0.03, Yahoo Finance reports.
Alpha Cognition Trading Up 4.5 %
ACOGF traded up C$0.02 during midday trading on Tuesday, hitting C$0.46. 19,119 shares of the company traded hands, compared to its average volume of 74,791. The company has a market capitalization of C$54.38 million, a price-to-earnings ratio of -3.29 and a beta of 2.87. Alpha Cognition has a 52-week low of C$0.16 and a 52-week high of C$0.74. The business has a 50 day simple moving average of C$0.54 and a two-hundred day simple moving average of C$0.55.
Analyst Upgrades and Downgrades
Separately, Raymond James raised shares of Alpha Cognition from a “hold” rating to a “moderate buy” rating in a research report on Monday, July 15th.
Alpha Cognition Company Profile
Alpha Cognition Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062, an acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases.
Featured Stories
- Five stocks we like better than Alpha Cognition
- 3 Healthcare Dividend Stocks to Buy
- 3 High-Potential Stocks That Could Turn Into Multi-Baggers
- Dividend Capture Strategy: What You Need to Know
- CEO Swap: Starbucks Surges 22% on Hiring New CEO From Chipotle
- High Flyers: 3 Natural Gas Stocks for March 2022
- 3 Small Cap Stocks Insiders Are Actively Buying
Receive News & Ratings for Alpha Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Cognition and related companies with MarketBeat.com's FREE daily email newsletter.